CDKN1B and cancer: In addition, miR-31 inhibits the proliferation of serous ovarian carcinomas and other cancers [8], and the PLZF-microRNA-221/-222 pathway controls the progression of melanoma neoplasia through the down-modulation of p27Kip1/CDKN1B and the c-KIT receptor [9].